EMPA-REG OUTCOME ELIGIBILITY AND PREVENTABLE CARDIOVASCULAR EVENTS IN THE US POPULATION: AN ANALYSIS OF THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY

The EMPA-REG OUTCOME trial recently demonstrated in persons with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) the efficacy of empagliflozin in reducing CVD events, as well as heart failure hospitalizations, cardiac and total mortality. The potential impact of EMPA-REG